Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07454668 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

StatusNot Yet Recruiting
PhasePhase 1
Started2027-01
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jul 2028 → Feb 2029
See other at-risk trials from Baptist Health South Florida

Amendment history

2026-10-02
Primary completion pushed: 2028-07 → 2029-02
Completion pushed: 2029-07 → 2030-02
A phase I clinical trial (a type of research study) for people with human epidermal growth factor receptor 2 (HER-2) positive breast cancer with metastasis to the brain. This research study will evaluate how well brain metastases can be controlled using a type of radiation therapy known as stereotactic radiosurgery (SRS) when combined with the therapeutic agent Trastuzumab Deruxtecan (T-DXd). The combined use of SRS with T-DXd is considered investigational.
Trial Details
NCT Number NCT07454668
Lead Sponsor Baptist Health South Florida
Collaborators: National Brain Tumor Society
Conditions Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer, Cancer Metastatic
Enrollment 20 participants
Start Date 2027-01
Primary Completion 2029-02 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-10-01